SCHEMBL2575166

SCHEMBL2575166

Oc1ccccc1Cc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.61
MAPT P10636 2/20 0.61
MEN1 O00255 1/20 0.61
HTT P42858 1/20 0.61
RAB9A P51151 1/20 0.61
KMT2A Q03164 1/20 0.61
KEAP1 Q14145 1/20 0.58
CYP11B1 P15538 1/20 0.51
CYP11B2 P19099 1/20 0.51
HSPA5 P11021 1/20 0.48
SLC6A2 P23975 1/20 0.43
SLC6A3 Q01959 1/20 0.43
FFAR1 O14842 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
GRIN2B Q13224 3/20 0.42
MPO P05164 1/20 0.42
TRPV1 Q8NER1 2/20 0.42
EPHX1 P07099 1/20 0.41
NLRP3 Q96P20 1/20 0.41
PLA2G1B P04054 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8470716 0.85 MEN1 (0.60) SLC6A4MAPTMEN1HTTRAB9A
SCHEMBL2573764 0.83 MEN1 (0.50) SLC6A4MAPTMEN1HTTRAB9A
SCHEMBL28194119 0.80 SLC6A4 (0.61) SLC6A4MAPTMEN1HTTRAB9A
SCHEMBL9776607 0.80 KEAP1 (0.86) MEN1KMT2AKEAP1HSPA5
SCHEMBL30616875 0.80 KEAP1 (0.86) MEN1KMT2AKEAP1HSPA5
SCHEMBL4279587 0.80 SLC6A4 (0.47) SLC6A4MAPTMEN1HTTRAB9A
SCHEMBL16770891 0.78 SLC6A4 (0.58) SLC6A4MAPTCYP11B1CYP11B2GRIN2B
SCHEMBL2092054 0.78 SLC6A4 (0.56) SLC6A4MAPTCYP11B1CYP11B2GRIN2B
SCHEMBL15079889 0.78 MEN1 (0.58) SLC6A4MAPTMEN1HTTRAB9A
SCHEMBL2576294 0.77 KEAP1 (0.63) MAPTRAB9AKEAP1HSPA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048897-B2 Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-01 US disclosed
CN-101010276-B Cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing same CHUGAI PHARMACEUTICAL CO LTD 2011-01-12 CN disclosed
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-12-25 US disclosed
CN-101010276-A Novel cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing the same CHUGAI PHARMACEUTICAL CO LTD (JP) 2007-08-01 CN disclosed
EP-1783110-A1 NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes SLC5A1, GPR119, SLC5A2 SLC6A4 2751/4885MAPT 4638/4885MEN1 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.